{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T20:42:31Z","timestamp":1793479351458,"version":"4.5.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T00:00:00Z","timestamp":1489017600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1038\/nrrheum.2017.15","type":"journal-article","created":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T00:02:07Z","timestamp":1489017727000},"page":"331-339","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":150,"title":["Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis"],"prefix":"10.1038","volume":"13","author":[{"given":"Leendert A.","family":"Trouw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Rispens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene E. M.","family":"Toes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,9]]},"reference":[{"key":"BFnrrheum201715_CR1","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1084\/jem.20160792","volume":"213","author":"EM Tan","year":"2016","unstructured":"Tan, E. M. & Smolen, J. S. Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor. J. Exp. Med. 213, 1937\u20131950 (2016).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum201715_CR2","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/j.1600-0463.2007.apm_682a.x","volume":"115","author":"E Waaler","year":"2007","unstructured":"Waaler, E. On the occurrence of a factor in human serum activating the specific agglutintion of sheep blood corpuscles. 1939. APMIS 115, 422\u2013438 (2007).","journal-title":"APMIS"},{"key":"BFnrrheum201715_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1084\/jem.108.1.105","volume":"108","author":"GM Edelman","year":"1958","unstructured":"Edelman, G. M., Kunkel, H. G. & Franklin, E. C. Interaction of the rheumatoid factor with antigen-antibody complexes and aggregated gamma globulin. J. Exp. Med. 108, 105\u2013120 (1958).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum201715_CR4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4049\/jimmunol.77.3.181","volume":"77","author":"JH Vaughan","year":"1956","unstructured":"Vaughan, J. H. Behavior of the rheumatoid arthritis agglutinating factor with immune precipitates. J. Immunol. 77, 181\u2013188 (1956).","journal-title":"J. Immunol."},{"key":"BFnrrheum201715_CR5","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1136\/ard.23.4.302","volume":"23","author":"RL Nienhuis","year":"1964","unstructured":"Nienhuis, R. L. & Mandema, E. A new serum factor in patients with rheumatoid arthritis; the antiperinuclear factor. Ann. Rheum. Dis. 23, 302\u2013305 (1964).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201715_CR6","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1146\/annurev.immunol.26.021607.090244","volume":"26","author":"L Klareskog","year":"2008","unstructured":"Klareskog, L. et al. Immunity to citrullinated proteins in rheumatoid arthritis. Annu. Rev. Immunol. 26, 651\u2013675 (2008).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrrheum201715_CR7","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha, D. et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann. Rheum. Dis. 69, 1580\u20131588 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201715_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.autrev.2013.10.008","volume":"13","author":"J Shi","year":"2014","unstructured":"Shi, J. et al. Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. Autoimmun. Rev. 13, 225\u2013230 (2014).","journal-title":"Autoimmun. Rev."},{"key":"BFnrrheum201715_CR9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1365-2796.2012.02514.x","volume":"271","author":"A Cerami","year":"2012","unstructured":"Cerami, A. The unexpected pathway to the creation of the HbA1c test and the discovery of AGE's. J. Intern. Med. 271, 219\u2013226 (2012).","journal-title":"J. Intern. Med."},{"key":"BFnrrheum201715_CR10","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1016\/j.joca.2015.05.016","volume":"23","author":"A Courties","year":"2015","unstructured":"Courties, A. et al. Metabolic stress-induced joint inflammation and osteoarthritis. Osteoarthritis Cartilage 23, 1955\u20131965 (2015).","journal-title":"Osteoarthritis Cartilage"},{"key":"BFnrrheum201715_CR11","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1084\/jem.20121486","volume":"210","author":"K Amara","year":"2013","unstructured":"Amara, K. et al. Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition. J. Exp. Med. 210, 445\u2013455 (2013).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum201715_CR12","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/j.1365-2249.2004.02708.x","volume":"139","author":"S Chapuy-Regaud","year":"2005","unstructured":"Chapuy-Regaud, S. et al. IgG subclass distribution of the rheumatoid arthritis-specific autoantibodies to citrullinated fibrin. Clin. Exp. Immunol. 139, 542\u2013550 (2005).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrrheum201715_CR13","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1002\/art.22279","volume":"54","author":"KN Verpoort","year":"2006","unstructured":"Verpoort, K. N. et al. Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum. 54, 3799\u20133808 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201715_CR14","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1002\/art.39660","volume":"68","author":"K Chemin","year":"2016","unstructured":"Chemin, K. et al. A novel HLA-DRB1*10:01-restricted T cell epitope from citrullinated type II collagen relevant to rheumatoid arthritis. Arthritis Rheumatol. 68, 1124\u20131135 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum201715_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/art.25059","volume":"62","author":"AL Feitsma","year":"2010","unstructured":"Feitsma, A. L. et al. Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis. Arthritis Rheum. 62, 117\u2013125 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201715_CR16","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1084\/jem.20131241","volume":"210","author":"SW Scally","year":"2013","unstructured":"Scally, S. W. et al. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J. Exp. Med. 210, 2569\u20132582 (2013).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum201715_CR17","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1002\/art.30445","volume":"63","author":"O Snir","year":"2011","unstructured":"Snir, O. et al. Identification and functional characterization of T cells reactive to citrullinated vimentin in HLA-DRB1*0401-positive humanized mice and rheumatoid arthritis patients. Arthritis Rheum. 63, 2873\u20132883 (2011).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201715_CR18","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1002\/art.38637","volume":"66","author":"EA James","year":"2014","unstructured":"James, E. A. et al. Citrulline-specific Th1 cells are increased in rheumatoid arthritis and their frequency is influenced by disease duration and therapy. Arthritis Rheumatol. 66, 1712\u20131722 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum201715_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1084\/jem.20101574","volume":"208","author":"JJ Sabatino Jr","year":"2011","unstructured":"Sabatino, J. J. Jr et al. High prevalence of low affinity peptide-MHC II tetramer-negative effectors during polyclonal CD4+ T cell responses. J. Exp. Med. 208, 81\u201390 (2011).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum201715_CR20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.immuni.2006.06.009","volume":"25","author":"D Zehn","year":"2006","unstructured":"Zehn, D. & Bevan, M. J. T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. Immunity 25, 261\u2013270 (2006).","journal-title":"Immunity"},{"key":"BFnrrheum201715_CR21","first-page":"647","volume":"33","author":"C Anzilotti","year":"2006","unstructured":"Anzilotti, C. et al. Antibodies to viral citrullinated peptide in rheumatoid arthritis. J. Rheumatol. 33, 647\u2013651 (2006).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201715_CR22","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/art.39455","volume":"68","author":"S Li","year":"2016","unstructured":"Li, S. et al. Autoantibodies from single circulating plasmablasts react with citrullinated antigens and Porphyromonas gingivalis in rheumatoid arthritis. Arthritis Rheumatol. 68, 614\u2013626 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum201715_CR23","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1136\/ard.2010.131102","volume":"70","author":"A Ioan-Facsinay","year":"2011","unstructured":"Ioan-Facsinay, A. et al. Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. Ann. Rheum. Dis. 70, 188\u2013193 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201715_CR24","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1136\/annrheumdis-2014-206785","volume":"75","author":"M Juarez","year":"2016","unstructured":"Juarez, M. et al. Identification of novel antiacetylated vimentin antibodies in patients with early inflammatory arthritis. Ann. Rheum. Dis. 75, 1099\u20131107 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201715_CR25","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1136\/annrheumdis-2012-201559","volume":"72","author":"J Shi","year":"2013","unstructured":"Shi, J. et al. Recognition of citrullinated and carbamylated proteins by human antibodies: specificity, cross-reactivity and the 'AMC-Senshu' method. Ann. Rheum. Dis. 72, 148\u2013150 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201715_CR26","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/rheumatology\/kes371","volume":"52","author":"LA van de Stadt","year":"2013","unstructured":"van de Stadt, L. A. et al. Monoclonal anti-citrullinated protein antibodies selected on citrullinated fibrinogen have distinct targets with different cross-reactivity patterns. Rheumatology (Oxford) 52, 631\u2013635 (2013).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum201715_CR27","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.smim.2015.11.001","volume":"27","author":"J Stamnaes","year":"2015","unstructured":"Stamnaes, J. & Sollid, L. M. Celiac disease: autoimmunity in response to food antigen. Semin. Immunol. 27, 343\u2013352 (2015).","journal-title":"Semin. Immunol."},{"key":"BFnrrheum201715_CR28","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1073\/pnas.0712250105","volume":"105","author":"M Griffioen","year":"2008","unstructured":"Griffioen, M. et al. Identification of phosphatidylinositol 4-kinase type II \u03b2 as HLA class II-restricted target in graft versus leukemia reactivity. Proc. Natl Acad. Sci. USA 105, 3837\u20133842 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum201715_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3324\/haematol.2013.086652","volume":"99","author":"AN Kremer","year":"2014","unstructured":"Kremer, A. N. et al. Development of a coordinated allo T cell and auto B cell response against autosomal PTK2B after allogeneic hematopoietic stem cell transplantation. Haematologica 99, 365\u2013369 (2014).","journal-title":"Haematologica"},{"key":"BFnrrheum201715_CR30","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1084\/jem.20031560","volume":"199","author":"E Zorn","year":"2004","unstructured":"Zorn, E. et al. Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J. Exp. Med. 199, 1133\u20131142 (2004).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum201715_CR31","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/j.1423-0410.1993.tb03065.x","volume":"64","author":"CK Osterland","year":"1993","unstructured":"Osterland, C. K., Harboe, M. & Kunkel, H. G. Anti-gammaglobulin factors in human sera revealed by enzymatic splitting of anti-Rh antibodies. Vox Sang 1963;8:133-52. Vox Sang. 64, 246\u2013247 (1993).","journal-title":"Vox Sang."},{"key":"BFnrrheum201715_CR32","first-page":"16","volume":"33","author":"GH Vos","year":"1977","unstructured":"Vos, G. H. Anti-fab' antibodies in human sera. I. A study of their distribution in health and disease. Vox Sang. 33, 16\u201320 (1977).","journal-title":"Vox Sang."},{"key":"BFnrrheum201715_CR33","first-page":"889","volume":"8","author":"OJ Mellbye","year":"1971","unstructured":"Mellbye, O. J. & Natvig, J. B. Evidence for immune complexes containing antibody to the pepsin site of IgG in rheumatoid synovial fluids. Clin. Exp. Immunol. 8, 889\u2013899 (1971).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrrheum201715_CR34","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jim.2011.09.011","volume":"375","author":"T Rispens","year":"2012","unstructured":"Rispens, T. et al. Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing. J. Immunol. Methods 375, 93\u201399 (2012).","journal-title":"J. Immunol. Methods"},{"key":"BFnrrheum201715_CR35","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/art.1780261210","volume":"26","author":"HH Birdsall","year":"1983","unstructured":"Birdsall, H. H., Lidsky, M. D. & Rossen, R. D. Anti-Fab' antibodies in rheumatoid arthritis. Measurement of the relative quantities incorporated in soluble immune complexes in sera and supernatants from cultured peripheral blood lymphocytes. Arthritis Rheum. 26, 1481\u20131492 (1983).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201715_CR36","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/j.1365-2249.1992.tb06974.x","volume":"89","author":"J Hassan","year":"1992","unstructured":"Hassan, J. et al. Prevalence of anti-Fab antibodies in patients with autoimmune and infectious diseases. Clin. Exp. Immunol. 89, 423\u2013426 (1992).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrrheum201715_CR37","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1172\/JCI112027","volume":"76","author":"JE Persselin","year":"1985","unstructured":"Persselin, J. E. & Stevens, R. H. Anti-Fab antibodies in humans. Predominance of minor immunoglobulin G subclasses in rheumatoid arthritis. J. Clin. Invest. 76, 723\u2013730 (1985).","journal-title":"J. Clin. Invest."},{"key":"BFnrrheum201715_CR38","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.molimm.2007.10.043","volume":"45","author":"MH Ryan","year":"2008","unstructured":"Ryan, M. H. et al. Proteolysis of purified IgGs by human and bacterial enzymes in vitro and the detection of specific proteolytic fragments of endogenous IgG in rheumatoid synovial fluid. Mol. Immunol. 45, 1837\u20131846 (2008).","journal-title":"Mol. Immunol."},{"key":"BFnrrheum201715_CR39","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s100670050004","volume":"19","author":"Y Kageyama","year":"2000","unstructured":"Kageyama, Y. et al. Levels of rheumatoid factor isotypes, metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in synovial fluid from various arthritides. Clin. Rheumatol. 19, 14\u201320 (2000).","journal-title":"Clin. Rheumatol."},{"key":"BFnrrheum201715_CR40","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1136\/ard.61.2.161","volume":"61","author":"C Ribbens","year":"2002","unstructured":"Ribbens, C. et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann. Rheum. Dis. 61, 161\u2013166 (2002).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201715_CR41","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/03009740701340172","volume":"36","author":"E Solau-Gervais","year":"2007","unstructured":"Solau-Gervais, E. et al. Cysteine and serine proteases of synovial tissue in rheumatoid arthritis and osteoarthritis. Scand. J. Rheumatol. 36, 373\u2013377 (2007).","journal-title":"Scand. J. Rheumatol."},{"key":"BFnrrheum201715_CR42","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1136\/ard.2003.013243","volume":"63","author":"I Tchetverikov","year":"2004","unstructured":"Tchetverikov, I. et al. MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis. Ann. Rheum. Dis. 63, 881\u2013883 (2004).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201715_CR43","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1126\/science.271.5247.348","volume":"271","author":"PW Dempsey","year":"1996","unstructured":"Dempsey, P. W. et al. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271, 348\u2013350 (1996).","journal-title":"Science"},{"key":"BFnrrheum201715_CR44","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4049\/jimmunol.1601096","volume":"198","author":"WJ Falkenburg","year":"2017","unstructured":"Falkenburg, W. J. et al. Anti-hinge antibodies recognize IgG subclass- and protease-restricted neoepitopes. J. Immunol. 198, 82\u201393 (2017).","journal-title":"J. Immunol."},{"key":"BFnrrheum201715_CR45","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1053\/j.gastro.2015.07.002","volume":"149","author":"P Biancheri","year":"2015","unstructured":"Biancheri, P. et al. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease. Gastroenterology 149, 1564\u20131574.e3 (2015).","journal-title":"Gastroenterology"},{"key":"BFnrrheum201715_CR46","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.4161\/mabs.29825","volume":"6","author":"RJ Brezski","year":"2014","unstructured":"Brezski, R. J. et al. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo. mAbs 6, 1265\u20131273 (2014).","journal-title":"mAbs"},{"key":"BFnrrheum201715_CR47","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1159\/000069457","volume":"115","author":"P Terness","year":"1998","unstructured":"Terness, P. & Opelz, G. Natural anti-immunoglobulin autoantibodies: irrelevant by-products or immunoregulatory molecules? Int. Arch. Allergy Immunol. 115, 270\u2013277 (1998).","journal-title":"Int. Arch. Allergy Immunol."},{"key":"BFnrrheum201715_CR48","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1073\/pnas.94.5.1902","volume":"94","author":"M Welschof","year":"1997","unstructured":"Welschof, M. et al. The antigen-binding domain of a human IgG-anti-F(ab')2 autoantibody. Proc. Natl Acad. Sci. USA 94, 1902\u20131907 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum201715_CR49","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S0198-8859(98)00132-3","volume":"60","author":"M Welschof","year":"1999","unstructured":"Welschof, M. et al. The antigen binding domain of non-idiotypic human anti-F(ab')2 autoantibodies: study of their interaction with IgG hinge region epitopes. Hum. Immunol. 60, 282\u2013290 (1999).","journal-title":"Hum. Immunol."},{"key":"BFnrrheum201715_CR50","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.4049\/jimmunol.181.5.3183","volume":"181","author":"RJ Brezski","year":"2008","unstructured":"Brezski, R. J. et al. Human anti-IgG1 hinge autoantibodies reconstitute the effector functions of proteolytically inactivated IgGs. J. Immunol. 181, 3183\u20133192 (2008).","journal-title":"J. Immunol."},{"key":"BFnrrheum201715_CR51","doi-asserted-by":"publisher","first-page":"17864","DOI":"10.1073\/pnas.0904174106","volume":"106","author":"RJ Brezski","year":"2009","unstructured":"Brezski, R. J. et al. Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge. Proc. Natl Acad. Sci. USA 106, 17864\u201317869 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum201715_CR52","doi-asserted-by":"publisher","first-page":"212","DOI":"10.4161\/mabs.2.3.11780","volume":"2","author":"RJ Brezski","year":"2010","unstructured":"Brezski, R. J. & Jordan, R. E. Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity? mAbs 2, 212\u2013220 (2010).","journal-title":"mAbs"},{"key":"BFnrrheum201715_CR53","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1002\/art.38335","volume":"66","author":"LA van de Stadt","year":"2014","unstructured":"van de Stadt, L. A. et al. Antibodies to IgG4 hinge can be found in rheumatoid arthritis patients during all stages of disease and may exacerbate chronic antibody-mediated inflammation. Arthritis Rheumatol. 66, 1133\u20131140 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum201715_CR54","doi-asserted-by":"publisher","unstructured":"Hosp, F. et al. Lysine acetylation in mitochondria: from inventory to function. Mitochondrion http:\/\/dx.doi.org\/10.1016\/j.mito.2016.07.012 (2016).","DOI":"10.1016\/j.mito.2016.07.012"},{"key":"BFnrrheum201715_CR55","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/annrheumdis-2016-209297","volume":"76","author":"CP Figueiredo","year":"2016","unstructured":"Figueiredo, C. P. et al. Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs. Ann. Rheum. Dis. 76, 399\u2013407 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201715_CR56","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.freeradbiomed.2010.08.001","volume":"49","author":"MJ Duryee","year":"2010","unstructured":"Duryee, M. J. et al. Malondialdehyde-acetaldehyde adduct is the dominant epitope after MDA modification of proteins in atherosclerosis. Free Radic. Biol. Med. 49, 1480\u20131486 (2010).","journal-title":"Free Radic. Biol. Med."},{"key":"BFnrrheum201715_CR57","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.freeradbiomed.2015.09.003","volume":"89","author":"DT Antoniak","year":"2015","unstructured":"Antoniak, D. T. et al. Aldehyde-modified proteins as mediators of early inflammation in atherosclerotic disease. Free Radic. Biol. Med. 89, 409\u2013418 (2015).","journal-title":"Free Radic. Biol. Med."},{"key":"BFnrrheum201715_CR58","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1007\/s00296-011-1964-1","volume":"32","author":"R Mishra","year":"2012","unstructured":"Mishra, R. et al. A comparative analysis of serological parameters and oxidative stress in osteoarthritis and rheumatoid arthritis. Rheumatol. Int. 32, 2377\u20132382 (2012).","journal-title":"Rheumatol. Int."},{"key":"BFnrrheum201715_CR59","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/art.38969","volume":"67","author":"GM Thiele","year":"2015","unstructured":"Thiele, G. M. et al. Malondialdehyde-acetaldehyde adducts and anti-malondialdehyde-acetaldehyde antibodies in rheumatoid arthritis. Arthritis Rheumatol. 67, 645\u2013655 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum201715_CR60","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1373\/clinchem.2011.163188","volume":"57","author":"S Jaisson","year":"2011","unstructured":"Jaisson, S., Pietrement, C. & Gillery, P. Carbamylation-derived products: bioactive compounds and potential biomarkers in chronic renal failure and atherosclerosis. Clin. Chem. 57, 1499\u20131505 (2011).","journal-title":"Clin. Chem."},{"key":"BFnrrheum201715_CR61","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1056\/NEJM198104023041406","volume":"304","author":"R Fluckiger","year":"1981","unstructured":"Fluckiger, R. et al. Hemoglobin carbamylation in uremia. N. Engl. J. Med. 304, 823\u2013827 (1981).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201715_CR62","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.cca.2016.06.009","volume":"460","author":"S Jaisson","year":"2016","unstructured":"Jaisson, S. et al. Homocitrulline as marker of protein carbamylation in hemodialyzed patients. Clin. Chim. Acta 460, 5\u201310 (2016).","journal-title":"Clin. Chim. Acta"},{"key":"BFnrrheum201715_CR63","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/nm1637","volume":"13","author":"Z Wang","year":"2007","unstructured":"Wang, Z. et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat. Med. 13, 1176\u20131184 (2007).","journal-title":"Nat. Med."},{"key":"BFnrrheum201715_CR64","first-page":"1830","volume":"20","author":"M Heliovaara","year":"1993","unstructured":"Heliovaara, M. et al. Smoking and risk of rheumatoid arthritis. J. Rheumatol. 20, 1830\u20131855 (1993).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201715_CR65","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1002\/art.27644","volume":"62","author":"S Turunen","year":"2010","unstructured":"Turunen, S. et al. Anticitrulline antibodies can be caused by homocitrulline-containing proteins in rabbits. Arthritis Rheum. 62, 3345\u20133352 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201715_CR66","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0014-4835(87)80067-2","volume":"45","author":"HT Beswick","year":"1987","unstructured":"Beswick, H. T. & Harding, J. J. High-molecular-weight crystallin aggregate formation resulting from non-enzymic carbamylation of lens crystallins: relevance to cataract formation. Exp. Eye Res. 45, 569\u2013578 (1987).","journal-title":"Exp. Eye Res."},{"key":"BFnrrheum201715_CR67","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1002\/eji.201444869","volume":"44","author":"C Koro","year":"2014","unstructured":"Koro, C. et al. Carbamylation of immunoglobulin abrogates activation of the classical complement pathway. Eur. J. Immunol. 44, 3403\u20133412 (2014).","journal-title":"Eur. J. Immunol."},{"key":"BFnrrheum201715_CR68","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1089\/ars.2012.4535","volume":"19","author":"O Kummu","year":"2013","unstructured":"Kummu, O. et al. Carbamyl adducts on low-density lipoprotein induce IgG response in LDLR\u2212\/\u2212 mice and bind plasma autoantibodies in humans under enhanced carbamylation. Antioxid. Redox Signal. 19, 1047\u20131062 (2013).","journal-title":"Antioxid. Redox Signal."},{"key":"BFnrrheum201715_CR69","doi-asserted-by":"publisher","first-page":"6882","DOI":"10.4049\/jimmunol.1000075","volume":"184","author":"P Mydel","year":"2010","unstructured":"Mydel, P. et al. Carbamylation-dependent activation of T cells: a novel mechanism in the pathogenesis of autoimmune arthritis. J. Immunol. 184, 6882\u20136890 (2010).","journal-title":"J. Immunol."},{"key":"BFnrrheum201715_CR70","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0022-2275(20)37720-8","volume":"25","author":"UP Steinbrecher","year":"1984","unstructured":"Steinbrecher, U. P. et al. Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: generation of antibodies specific for derivatized lysine. J. Lipid Res. 25, 1109\u20131116 (1984).","journal-title":"J. Lipid Res."},{"key":"BFnrrheum201715_CR71","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13075-015-0690-6","volume":"17","author":"KM Janssen","year":"2015","unstructured":"Janssen, K. M. et al. Rheumatoid arthritis-associated autoantibodies in non-rheumatoid arthritis patients with mucosal inflammation: a case-control study. Arthritis Res. Ther. 17, 174 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201715_CR72","doi-asserted-by":"publisher","first-page":"e0159000","DOI":"10.1371\/journal.pone.0159000","volume":"11","author":"L Li","year":"2016","unstructured":"Li, L. et al. Meta-analysis: diagnostic accuracy of anti-carbamylated protein antibody for rheumatoid arthritis. PLoS ONE 11, e0159000 (2016).","journal-title":"PLoS ONE"},{"key":"BFnrrheum201715_CR73","doi-asserted-by":"publisher","first-page":"17372","DOI":"10.1073\/pnas.1114465108","volume":"108","author":"J Shi","year":"2011","unstructured":"Shi, J. et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc. Natl Acad. Sci. USA 108, 17372\u201317377 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum201715_CR74","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s13075-015-0860-6","volume":"17","author":"J Shi","year":"2015","unstructured":"Shi, J. et al. The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis. Arthritis Res. Ther. 17, 339 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201715_CR75","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1136\/annrheumdis-2016-209248","volume":"75","author":"MK Verheul","year":"2016","unstructured":"Verheul, M. K. et al. Anti-carbamylated protein antibodies: a specific hallmark for rheumatoid arthritis. Comparison to conditions known for enhanced carbamylation; renal failure, smoking and chronic inflammation. Ann. Rheum. Dis. 75, 1575\u20131576 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201715_CR76","doi-asserted-by":"publisher","first-page":"e102163","DOI":"10.1371\/journal.pone.0102163","volume":"9","author":"JN Stoop","year":"2014","unstructured":"Stoop, J. N. et al. Antibodies specific for carbamylated proteins precede the onset of clinical symptoms in mice with collagen induced arthritis. PLoS ONE 9, e102163 (2014).","journal-title":"PLoS ONE"},{"key":"BFnrrheum201715_CR77","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1136\/annrheumdis-2014-206797","volume":"74","author":"JN Stoop","year":"2015","unstructured":"Stoop, J. N. et al. Anticarbamylated protein antibodies can be detected in animal models of arthritis that require active involvement of the adaptive immune system. Ann. Rheum. Dis. 74, 949\u2013950 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201715_CR78","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13075-015-0536-2","volume":"17","author":"M Brink","year":"2015","unstructured":"Brink, M. et al. Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage. Arthritis Res. Ther. 17, 25 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201715_CR79","doi-asserted-by":"publisher","first-page":"572","DOI":"10.3899\/jrheum.140767","volume":"42","author":"RW Gan","year":"2015","unstructured":"Gan, R. W. et al. Anti-carbamylated protein antibodies are present prior to rheumatoid arthritis and are associated with its future diagnosis. J. Rheumatol. 42, 572\u2013579 (2015).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201715_CR80","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/annrheumdis-2013-204154","volume":"73","author":"J Shi","year":"2014","unstructured":"Shi, J. et al. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann. Rheum. Dis. 73, 780\u2013783 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201715_CR81","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1136\/annrheumdis-2013-205109","volume":"73","author":"X Jiang","year":"2014","unstructured":"Jiang, X. et al. Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. Ann. Rheum. Dis. 73, 1761\u20131768 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201715_CR82","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3899\/jrheum.130742","volume":"41","author":"M Scinocca","year":"2014","unstructured":"Scinocca, M. et al. Antihomocitrullinated fibrinogen antibodies are specific to rheumatoid arthritis and frequently bind citrullinated proteins\/peptides. J. Rheumatol. 41, 270\u2013279 (2014).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201715_CR83","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13075-016-1001-6","volume":"18","author":"E Reed","year":"2016","unstructured":"Reed, E. et al. Antibodies to carbamylated \u03b1-enolase epitopes in rheumatoid arthritis also bind citrullinated epitopes and are largely indistinct from anti-citrullinated protein antibodies. Arthritis Res. Ther. 18, 96 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201715_CR84","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13075-014-0515-z","volume":"17","author":"S Turunen","year":"2015","unstructured":"Turunen, S. et al. Separate and overlapping specificities in rheumatoid arthritis antibodies binding to citrulline- and homocitrulline-containing peptides related to type I and II collagen telopeptides. Arthritis Res. Ther. 17, 2 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201715_CR85","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1136\/annrheumdis-2015-208870","volume":"76","author":"S Ajeganova","year":"2016","unstructured":"Ajeganova, S. et al. The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor. Ann. Rheum. Dis. 76, 112\u2013118 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201715_CR86","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1093\/rheumatology\/kev250","volume":"54","author":"MK Verheul","year":"2015","unstructured":"Verheul, M. K. et al. Anti-carbamylated protein antibodies in rheumatoid arthritis patients of Asian descent. Rheumatology (Oxford) 54, 1930\u20131932 (2015).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum201715_CR87","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1002\/art.21385","volume":"52","author":"TWJ Huizinga","year":"2005","unstructured":"Huizinga, T. W. J. et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum. 52, 3433\u20133438 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201715_CR88","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1002\/art.21302","volume":"52","author":"KN Verpoort","year":"2005","unstructured":"Verpoort, K. N. et al. Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis. Arthritis Rheum. 52, 3058\u20133062 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201715_CR89","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/1479-5876-11-224","volume":"11","author":"S Turunen","year":"2013","unstructured":"Turunen, S. et al. Different amounts of protein-bound citrulline and homocitrulline in foot joint tissues of a patient with anti-citrullinated protein antibody positive erosive rheumatoid arthritis. J. Transl. Med. 11, 224 (2013).","journal-title":"J. Transl. Med."},{"key":"BFnrrheum201715_CR90","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1073\/pnas.1517096113","volume":"113","author":"L Gorisse","year":"2016","unstructured":"Gorisse, L. et al. Protein carbamylation is a hallmark of aging. Proc. Natl Acad. Sci. USA 113, 1191\u20131196 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum201715_CR91","doi-asserted-by":"publisher","first-page":"e000172","DOI":"10.1136\/rmdopen-2015-000172","volume":"2","author":"G Akdemir","year":"2016","unstructured":"Akdemir, G. et al. Predictive factors of radiological progression after 2 years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED study. RMD Open 2, e000172 (2016).","journal-title":"RMD Open"},{"key":"BFnrrheum201715_CR92","first-page":"824","volume":"33","author":"C Alessandri","year":"2015","unstructured":"Alessandri, C. et al. Anti-carbamylated protein antibodies in unaffected first-degree relatives of rheumatoid arthritis patients: lack of correlation with anti-cyclic citrullinated protein antibodies and rheumatoid factor. Clin. Exp. Rheumatol. 33, 824\u2013830 (2015).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum201715_CR93","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3899\/jrheum.150179","volume":"43","author":"GJ Challener","year":"2016","unstructured":"Challener, G. J. et al. Anti-carbamylated protein antibody levels correlate with anti-Sa (citrullinated vimentin) antibody levels in rheumatoid arthritis. J. Rheumatol. 43, 273\u2013281 (2016).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201715_CR94","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1136\/annrheumdis-2015-207326","volume":"75","author":"JH Humphreys","year":"2016","unstructured":"Humphreys, J. H. et al. Anticarbamylated protein antibodies are associated with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. Ann. Rheum. Dis. 75, 1139\u20131144 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201715_CR95","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1002\/art.39664","volume":"68","author":"H Koppejan","year":"2016","unstructured":"Koppejan, H. et al. Role of anti-carbamylated protein antibodies compared to anti-citrullinated protein antibodies in indigenous North Americans with rheumatoid arthritis, their first-degree relatives and healthy controls. Arthritis Rheumatol. 68, 2090\u20132098 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum201715_CR96","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00296-016-3472-9","volume":"36","author":"G Martinez","year":"2016","unstructured":"Martinez, G. et al. Carbamylated vimentin represents a relevant autoantigen in Latin American (Cuban) rheumatoid arthritis patients. Rheumatol. Int. 36, 781\u2013791 (2016).","journal-title":"Rheumatol. Int."},{"key":"BFnrrheum201715_CR97","doi-asserted-by":"publisher","first-page":"e0161141","DOI":"10.1371\/journal.pone.0161141","volume":"11","author":"A Montes","year":"2016","unstructured":"Montes, A. et al. Anti-carbamylated protein antibodies as a reproducible independent type of rheumatoid arthritis autoantibodies. PLoS ONE 11, e0161141 (2016).","journal-title":"PLoS ONE"},{"key":"BFnrrheum201715_CR98","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12026-014-8560-x","volume":"61","author":"A Yee","year":"2015","unstructured":"Yee, A. et al. Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis. Immunol. Res. 61, 24\u201330 (2015).","journal-title":"Immunol. Res."},{"key":"BFnrrheum201715_CR99","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1136\/annrheumdis-2013-203650","volume":"72","author":"PC Hissink Muller","year":"2013","unstructured":"Hissink Muller, P. C. et al. Anticarbamylated protein (anti-CarP) antibodies are present in sera of juvenile idiopathic arthritis (JIA) patients. Ann. Rheum. Dis. 72, 2053\u20132055 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201715_CR100","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1093\/rheumatology\/kev391","volume":"55","author":"M Lopez-Hoyos","year":"2016","unstructured":"Lopez-Hoyos, M. et al. Anti-carbamylated protein antibodies in patients with ageing associated inflammatory chronic disorders. Rheumatology (Oxford) 55, 764\u2013766 (2016).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum201715_CR101","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nrrheum.2011.204","volume":"8","author":"A Willemze","year":"2012","unstructured":"Willemze, A. et al. The influence of ACPA status and characteristics on the course of RA. Nat. Rev. Rheumatol. 8, 144\u2013152 (2012).","journal-title":"Nat. Rev. Rheumatol."},{"key":"BFnrrheum201715_CR102","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/art.37830","volume":"65","author":"J Shi","year":"2013","unstructured":"Shi, J. et al. Anti carbamylated protein antibodies (anti-CarP) are present in arthralgia patients and predict the development of rheumatoid arthritis. Arthritis Rheum. 65, 911\u2013915 (2013).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201715_CR103","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo, M. L. et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38, 44\u201348 (1995).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201715_CR104","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1136\/annrheumdis-2015-208954","volume":"75","author":"S Ajeganova","year":"2016","unstructured":"Ajeganova, S. et al. Evaluation of the association between anticarbamylated protein antibodies and the longitudinal course of functional ability in rheumatoid arthritis. Ann. Rheum. Dis. 75, e14 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201715_CR105","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1136\/annrheumdis-2015-208579","volume":"75","author":"S Ajeganova","year":"2016","unstructured":"Ajeganova, S. et al. Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts. Ann. Rheum. Dis. 75, 1924\u20131932 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201715_CR106","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.autrev.2012.05.007","volume":"12","author":"LA Trouw","year":"2012","unstructured":"Trouw, L. A. & Mahler, M. Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. Autoimmun. Rev. 12, 318\u2013322 (2012).","journal-title":"Autoimmun. Rev."},{"key":"BFnrrheum201715_CR107","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nrrheum.2016.151","volume":"12","author":"LA Trouw","year":"2016","unstructured":"Trouw, L. A. & Toes, R. E. Rheumatoid arthritis: autoantibody testing to predict response to therapy in RA. Nat. Rev. Rheumatol. 12, 566\u2013568 (2016).","journal-title":"Nat. Rev. Rheumatol."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2017.15.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2017.15","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nrrheum.2017.15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2017.15.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T11:10:35Z","timestamp":1692702635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2017.15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,9]]},"references-count":107,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["BFnrrheum201715"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2017.15","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,9]]},"assertion":[{"value":"9 March 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.A.T. and R.E.M.T are listed as inventors on a patent for a method related to the detection of anti-CarP antibodies in arthritis (EP2671078B1).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}